#1 Clinical Trials Search in Europe

(-)-PHENSERINE TARTRATE

This article discusses clinical trials investigating (-)-PHENSERINE TARTRATE, an investigational drug being studied for the treatment of Alzheimer’s disease and mild cognitive impairment. The trials aim to evaluate the drug’s effects on specific biological markers related to brain cell health, comparing it to donepezil, an approved Alzheimer’s medication. These studies focus on patients with early or mild forms of Alzheimer’s disease.

Table of Contents

Overview of (-)-PHENSERINE TARTRATE Clinical Research

(-)-PHENSERINE TARTRATE is an investigational drug currently being studied in clinical trials for its potential to treat Alzheimer’s disease and mild cognitive impairment[1]. The research program focuses on understanding how this experimental medication affects various biological processes in the brain that are involved in cognitive decline and dementia.

The clinical development of (-)-PHENSERINE TARTRATE is in its early stages, with research teams conducting carefully designed studies to evaluate both the safety and potential effectiveness of the drug[1]. These trials represent important steps in determining whether (-)-PHENSERINE TARTRATE could eventually become a new treatment option for people experiencing memory and thinking problems related to Alzheimer’s disease.

The research approach involves comparing (-)-PHENSERINE TARTRATE directly with existing approved medications to understand how it performs relative to current treatment standards[1]. This comparative strategy helps researchers determine whether the investigational drug offers any advantages or different mechanisms of action compared to available therapies.

Phase 1 Dose Range Finding Study

A Phase 1 dose range finding study of (-)-PHENSERINE TARTRATE has been completed, representing the first stage of human testing for this investigational medication[1]. This trial was specifically designed to compare the effects of (-)-PHENSERINE TARTRATE with donepezil in participants who have early or mild Alzheimer’s disease.

The study is classified as an interventional trial, meaning that researchers actively administered specific treatments to participants and then carefully measured the resulting effects[1]. This type of research design allows scientists to directly observe how the drug behaves in the human body and what biological changes it produces.

The completed status of this trial indicates that all participant enrollment, treatment administration, and data collection have been finished[1]. Researchers are now analyzing the collected information to understand the drug’s effects and determine appropriate next steps in the development process.

During the study, participants received different dosing regimens of the medications being tested[1]. The interventions included:

  • (-)-PHENSERINE TARTRATE at 30 mg administered orally
  • Donepezil (ARICEPT) at 5 mg administered orally as film-coated tablets
  • Donepezil (ARICEPT) at 10 mg administered orally as film-coated tablets

The dose range finding aspect of this study means that researchers were working to identify the most appropriate and effective dose of (-)-PHENSERINE TARTRATE while minimizing potential side effects[1]. This information is crucial for planning larger, more advanced clinical trials.

Target Conditions: Alzheimer’s Disease and Mild Cognitive Impairment

The clinical trial of (-)-PHENSERINE TARTRATE specifically targets two related conditions: Alzheimer’s disease and mild cognitive impairment[1]. Understanding these conditions helps explain why researchers are interested in developing new treatments like (-)-PHENSERINE TARTRATE.

Alzheimer’s disease is a progressive brain disorder that gradually destroys memory, thinking skills, and eventually the ability to carry out simple tasks[1]. In the early or mild stages of Alzheimer’s disease, people may experience:

  • Memory loss that disrupts daily life, particularly forgetting recently learned information
  • Challenges in planning or solving problems
  • Difficulty completing familiar tasks at home, work, or leisure
  • Confusion with time or place
  • Trouble understanding visual images and spatial relationships
  • Problems with words in speaking or writing

Mild cognitive impairment represents a stage between normal age-related cognitive decline and more serious dementia[1]. People with this condition notice changes in their cognitive function, and these changes may be evident to family and friends, but they don’t significantly interfere with daily activities and independence. Some individuals with mild cognitive impairment will eventually develop Alzheimer’s disease, making it an important target for early intervention research.

The focus on early or mild stages of these conditions in the (-)-PHENSERINE TARTRATE trial reflects a research strategy aimed at intervening when brain damage may be less extensive[1]. Many researchers believe that treatments may be more effective when started earlier in the disease process, before significant irreversible brain damage has occurred.

Study Participants and Eligibility

The completed Phase 1 trial of (-)-PHENSERINE TARTRATE enrolled a total of 16 participants[1]. This relatively small number of participants is typical for Phase 1 studies, which are designed to provide initial information about safety and biological effects rather than definitive proof of effectiveness.

All participants in the study had either early or mild Alzheimer’s disease or mild cognitive impairment[1]. This specific patient population was chosen because these individuals are at a stage where new treatments might potentially slow disease progression or improve symptoms.

The selection of participants for clinical trials involves careful screening to ensure that enrolled individuals meet specific criteria[1]. While the detailed eligibility requirements for this particular trial are determined by the research team, studies in this patient population typically consider factors such as:

  • Confirmation of cognitive impairment through standardized testing
  • Severity of symptoms consistent with early or mild disease stages
  • Overall health status and ability to participate in study procedures
  • Absence of other conditions that might interfere with study results
  • Ability to provide informed consent or have a legal representative who can do so

The small size of this initial trial allowed researchers to closely monitor each participant and collect detailed information about how (-)-PHENSERINE TARTRATE affects various biological markers[1]. This intensive approach is characteristic of early-phase research, where the goal is to gather comprehensive data that will inform the design of larger studies.

Primary Outcomes and Biomarkers

The primary outcome of the (-)-PHENSERINE TARTRATE trial focuses on measuring changes in specific exosome biomarkers in participants treated with the investigational drug compared to those treated with donepezil[1]. This approach represents a sophisticated method of understanding how the drug affects biological processes at the cellular level.

Exosomes are tiny particles released by cells throughout the body, including brain cells[1]. These particles contain proteins, genetic material, and other molecules that provide information about what is happening inside cells. By analyzing exosomes found in blood samples, researchers can gain insights into brain cell health without needing to directly sample brain tissue.

The trial specifically examines exosome biomarkers related to four key areas of brain health[1]:

  • Pre-programmed cell death: This refers to the natural process by which damaged or unnecessary cells self-destruct in a controlled manner. In Alzheimer’s disease, abnormal patterns of cell death contribute to the loss of brain cells and cognitive decline. The trial measures whether (-)-PHENSERINE TARTRATE affects markers of this process differently than donepezil.
  • Synaptic integrity and function: Synapses are the connections between brain cells that allow them to communicate with each other. The health and proper functioning of these connections are essential for memory and thinking. Loss of synaptic integrity is one of the earliest changes in Alzheimer’s disease. Researchers are examining whether (-)-PHENSERINE TARTRATE influences biomarkers that reflect the health of these crucial connections.
  • Neuroinflammation: This term describes inflammation occurring in the brain and nervous system. While some inflammation is part of the body’s normal defense system, chronic neuroinflammation is believed to contribute to brain cell damage in Alzheimer’s disease. The trial evaluates whether (-)-PHENSERINE TARTRATE affects markers of inflammation in the brain.
  • AD-related protein trafficking: Protein trafficking refers to how proteins are transported to different locations within and between cells. In Alzheimer’s disease, abnormal processing and trafficking of certain proteins, particularly amyloid and tau proteins, lead to the formation of harmful deposits in the brain. The study examines whether (-)-PHENSERINE TARTRATE influences biomarkers related to these protein transport processes.

By measuring these diverse biomarkers, researchers aim to understand the multiple ways in which (-)-PHENSERINE TARTRATE might affect the biological processes underlying Alzheimer’s disease[1]. This comprehensive approach provides a more complete picture of the drug’s potential mechanisms of action than would be possible by looking at a single outcome measure.

Comparison with Donepezil

A key feature of the (-)-PHENSERINE TARTRATE trial is the direct comparison with donepezil, a medication already approved for treating Alzheimer’s disease[1]. Donepezil, marketed under the brand name ARICEPT, is one of the most commonly prescribed medications for managing symptoms of Alzheimer’s disease.

Donepezil works by preventing the breakdown of acetylcholine, a chemical messenger in the brain that is important for memory and thinking[1]. In Alzheimer’s disease, levels of acetylcholine are reduced, and donepezil helps maintain higher levels of this important neurotransmitter. The medication can help improve or stabilize symptoms in some people with Alzheimer’s disease, although it does not cure the disease or stop its progression.

In the clinical trial, participants received either (-)-PHENSERINE TARTRATE or donepezil, allowing researchers to compare the effects of the two medications on the measured biomarkers[1]. The donepezil doses used in the study were 5 mg and 10 mg, which are standard therapeutic doses for this medication.

This comparative design serves several important purposes[1]:

  • It provides a benchmark against which to evaluate (-)-PHENSERINE TARTRATE’s effects, using a medication with known activity in Alzheimer’s disease
  • It helps researchers understand whether (-)-PHENSERINE TARTRATE affects the same or different biological pathways compared to an established treatment
  • It offers initial insights into whether (-)-PHENSERINE TARTRATE might offer advantages over current therapies
  • It generates data that can help inform the design of future trials and the positioning of (-)-PHENSERINE TARTRATE in the treatment landscape if it proves successful

The comparison with donepezil is particularly valuable because it allows researchers to contextualize their findings within the framework of existing treatment options[1]. If (-)-PHENSERINE TARTRATE shows different patterns of effects on the measured biomarkers compared to donepezil, this could suggest that it works through different mechanisms or affects different aspects of Alzheimer’s disease pathology.

The use of multiple doses of donepezil in the study also provides additional comparative information, allowing researchers to see how (-)-PHENSERINE TARTRATE’s effects compare to both lower and higher doses of the approved medication[1]. This dose-response information can be valuable for understanding the relative potency and effects of the investigational drug.

Trial ID Phase Condition Studied Status Enrollment Primary Outcome
2023-510282-10-00 Phase 1 Mild Cognitive Impairment, Alzheimer’s disease Completed 16 participants Changes in exosome biomarkers of cell death, synaptic integrity, neuroinflammation, and protein trafficking compared to donepezil

FAQ

  • What is being studied in clinical trials of (-)-PHENSERINE TARTRATE? Clinical trials are investigating (-)-PHENSERINE TARTRATE as a potential treatment for Alzheimer's disease and mild cognitive impairment. The studies are comparing its effects on brain cell health markers to those of donepezil, an approved medication for Alzheimer's disease.
  • Who can participate in (-)-PHENSERINE TARTRATE clinical trials? The trials are enrolling participants with early or mild Alzheimer's disease, as well as those with mild cognitive impairment. Specific eligibility criteria are determined by the research team conducting each study.
  • What phase are the (-)-PHENSERINE TARTRATE trials in? The current clinical trial investigating (-)-PHENSERINE TARTRATE is a Phase 1 study, which is an early stage of drug development focused on safety and initial effectiveness. This phase helps researchers understand how the drug works in humans and determine appropriate dosing.
  • How many people are participating in these trials? The completed Phase 1 trial enrolled 16 participants with early or mild Alzheimer's disease or mild cognitive impairment. This relatively small number is typical for early-phase studies.
  • What is the trial measuring to determine if (-)-PHENSERINE TARTRATE works? The trial is measuring changes in specific biological markers found in exosomes, which are tiny particles released by cells. These markers indicate cell death, brain cell communication, inflammation, and protein processing related to Alzheimer's disease.

Ongoing Clinical Trials on (-)-PHENSERINE TARTRATE

  • Study on the Effects of Phenserine and Donepezil in Patients with Early or Mild Alzheimer’s Disease

    Not recruiting

    1 1 1
    Investigated drugs:
    Norway

Glossary

  • Alzheimer's Disease: A progressive brain disorder that causes memory loss, confusion, and changes in thinking and behavior. It is the most common cause of dementia in older adults.
  • Mild Cognitive Impairment: A condition where a person has noticeable memory or thinking problems that are worse than normal age-related changes but not severe enough to interfere significantly with daily life. It can sometimes progress to Alzheimer's disease.
  • Phase 1 Trial: The first stage of testing a new drug in humans, focusing on safety, dosage, and how the body processes the medication. These trials typically involve a small number of participants.
  • Exosome Biomarkers: Tiny particles released by cells that contain proteins and genetic material. Scientists measure these to understand what is happening inside cells and to track disease progression or treatment effects.
  • Pre-programmed Cell Death: A natural process where damaged or unnecessary cells self-destruct in a controlled way. Abnormal cell death is involved in many diseases, including Alzheimer's disease.
  • Synaptic Integrity: The health and proper functioning of synapses, which are the connections between brain cells that allow them to communicate with each other. Loss of synaptic integrity is a key feature of Alzheimer's disease.
  • Neuroinflammation: Inflammation occurring in the brain and nervous system. Chronic neuroinflammation is believed to contribute to the progression of Alzheimer's disease.
  • Donepezil: An approved medication used to treat symptoms of Alzheimer's disease by helping to improve memory and thinking. It is marketed under the brand name Aricept.
  • Dose Range Finding Study: A type of clinical trial designed to determine the most appropriate and effective dose of a medication while minimizing side effects.
  • Protein Trafficking: The process by which proteins are transported to different locations within and between cells. Abnormal protein trafficking is involved in the development of Alzheimer's disease.
  • Interventional Study: A type of clinical trial where researchers actively give participants a specific treatment or intervention and then measure the effects.
  • Primary Outcome: The main result that researchers are measuring in a clinical trial to determine if a treatment is effective. All other measurements are considered secondary.

References

  1. https://clinicaltrials.gov/study/2023-510282-10-00